Inpharma 1491 - 11 Jun 2005

■ Omalizumab [Xolair; Novartis] has been launchedin Canada for the treatment of moderate-to-severe,persistent asthma in adolescents and adults who havea positive skin test or in vitro reactivity to a perennialaeroallergen, and whose symptoms are inadequatelycontrolled with inhaled corticosteroids.Novartis Pharmaceuticals Canada Inc. (PR)Xolair*, first antibody therapy forasthma tackles underlying cause of asthma not just the symptoms. MediaRelease : 01 Jun 2005. Available from: URL: http://www.novartis.ca 809050166

1

Inpharma 11 Jun 2005 No. 14911173-8324/10/1491-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved